Back |
home / stock / apls / apls message board
Subject | By | Source | When |
---|---|---|---|
Heavy premium in the puts and calls. | IPO$ | investorshub | 02/08/2023 5:37:33 PM |
2/8/23 regulatory decision due on Empavali. | IPO$ | investorshub | 01/27/2023 4:11:13 PM |
znewcar1: ML41.15 LL11.45 off H73 | znewcar1 | investorshangout | 11/18/2022 3:05:49 PM |
Huge Market | conix | investorshub | 05/09/2022 5:54:02 PM |
Drug trial for dry $AMD slows progression of disease | conix | investorshub | 04/30/2022 2:28:04 PM |
Going back to 60 this week | PickleNick | investorshub | 11/13/2021 3:40:25 PM |
looks like insider dumping may be happening again.. damnit | wantprofits | investorshub | 01/09/2020 4:30:15 PM |
Be careful with this company. | Pedro2004 | investorshub | 01/08/2020 2:42:33 PM |
* * $APLS Video Chart 01-07-2020 * * | ClayTrader | investorshub | 01/07/2020 10:51:27 PM |
First! Holding $40 2/21 call... waiting on trial results! | ComptonBrosInc | investorshub | 12/31/2019 4:09:23 AM |
News, Short Squeeze, Breakout and More Instantly...
Apellis Pharmaceuticals Inc. Company Name:
APLS Stock Symbol:
NASDAQ Market:
Apellis Pharmaceuticals Inc. Website:
WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2024 financial results on Thursday, August 1, 2024, at 8:30 a.m. ET. To access ...
Late-breaking presentation shows SYFOVRE® (pegcetacoplan injection) demonstrated visual function benefit on prespecified endpoint in GALE long-term extension study WALTHAM, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that six ...
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the marketing authorization application (MAA) of i...